Teva Pharmaceutical Industries Limited (NYSE:TEVA) is Factorial Partners LLC's 3rd Largest Position

Factorial Partners LLC raised its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 14.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 311,000 shares of the company's stock after acquiring an additional 39,000 shares during the quarter. Teva Pharmaceutical Industries comprises 3.2% of Factorial Partners LLC's portfolio, making the stock its 3rd largest position. Factorial Partners LLC's holdings in Teva Pharmaceutical Industries were worth $5,604,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Sequoia Financial Advisors LLC grew its position in Teva Pharmaceutical Industries by 0.7% during the third quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company's stock valued at $2,025,000 after buying an additional 805 shares during the period. Signaturefd LLC lifted its position in Teva Pharmaceutical Industries by 16.9% in the third quarter. Signaturefd LLC now owns 7,583 shares of the company's stock valued at $137,000 after purchasing an additional 1,094 shares during the period. QRG Capital Management Inc. grew its position in shares of Teva Pharmaceutical Industries by 0.8% in the second quarter. QRG Capital Management Inc. now owns 144,938 shares of the company's stock valued at $2,355,000 after purchasing an additional 1,191 shares during the period. United Services Automobile Association raised its stake in Teva Pharmaceutical Industries by 3.1% during the second quarter. United Services Automobile Association now owns 41,159 shares of the company's stock valued at $669,000 after buying an additional 1,249 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 105.7% in the second quarter. GAMMA Investing LLC now owns 3,388 shares of the company's stock valued at $55,000 after buying an additional 1,741 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TEVA has been the topic of a number of recent analyst reports. StockNews.com raised shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research report on Thursday, October 17th. UBS Group lifted their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a "buy" rating in a report on Tuesday, September 3rd. Barclays upped their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 23rd. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, October 21st. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $19.67.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA traded up $0.22 on Wednesday, reaching $17.03. 6,261,762 shares of the company's stock were exchanged, compared to its average volume of 9,226,485. Teva Pharmaceutical Industries Limited has a fifty-two week low of $9.27 and a fifty-two week high of $19.31. The firm has a market capitalization of $19.29 billion, a price-to-earnings ratio of -19.76, a PEG ratio of 1.28 and a beta of 0.87. The business's 50-day moving average is $17.74 and its two-hundred day moving average is $17.30. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.